2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The Atrial fibrillation Better Care (ABC) pathway was proposed for a more holistic or integrated care approach to atrial fibrillation (AF) management. We investigated whether adherence with the ABC pathway reduced the risk of adverse clinical outcomes in real-world AF patients starting vitamin K antagonist (VKAs) therapy.

          Methods

          Prospective cohort study including AF outpatients starting VKA therapy from July 2016 to June 2018. Patients were considered as adherent if all ABC pathway criteria (A: Avoid stroke; B: Better symptom control; and C: Cardiovascular risk factors/comorbidities management) were fulfilled. The primary endpoints were all-cause mortality, net clinical outcomes (NCOs), major adverse cardiovascular events (MACE), and composite thrombotic/thromboembolic events at 2 years.

          Results

          We enrolled 1045 patients (51.6% female; median age 77 [70–83] years). Of these, 63.0% (658) were adherent to the ABC pathway and 37% (387) were considered non-adherent. Compared to non-adherent patients, those who were ABC adherent had lower event rates for all-cause mortality (13.76 vs. 6.56; p<0.001), NCOs (19.65 vs . 11.94; p<0.001), and MACE (11.88 vs. 7.75; p=0.006) during the follow-up. Adjusted Cox regression analyses demonstrated that the ABC pathway adherent care reduced the risks of all-cause mortality (aHR 0.57, 95% CI 0.42–0.78), NCOs (aHR 0.72, 95% CI 0.56–0.92), and cardiovascular mortality (aHR 0.54, 95% CI 0.32–0.90). Event-free survivals for all-cause mortality, NCOs (both log-rank p-values <0.001), and MACE (log-rank p-value = 0.004) were also higher in ABC pathway adherent patients.

          Conclusions

          In this real-world prospective cohort of AF patients starting VKA therapy, adherence to the ABC pathway management at baseline significantly reduced the risk of NCOs, all-cause mortality, and cardiovascular death at 2 years.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s11606-022-07567-5.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: not found
          • Article: not found

          OUP accepted manuscript

          (2020)
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

            Summary. A variety of definitions of major bleeding have been used in published clinical studies, and this diversity adds to the difficulty in comparing data between trials and in performing meta-analyses. In the first step towards unified definitions of bleeding complications, the definition of major bleeding in non-surgical patients was discussed at the Control of Anticoagulation Subcommittee of the International Society on Thrombosis and Haemostasis. Arising from that discussion, a definition was developed that should be applicable to studies with all agents that interfere with hemostasis, including anticoagulants, platelet function inhibitors and fibrinolytic drugs. The definition and the text that follows have been reviewed and approved by the cochairs of the subcommittee and the revised version is published here. The intention is to also seek approval of this definition from the regulatory authorities.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH.

                Bookmark

                Author and article information

                Contributors
                vroldans@um.es
                Journal
                J Gen Intern Med
                J Gen Intern Med
                Journal of General Internal Medicine
                Springer International Publishing (Cham )
                0884-8734
                1525-1497
                11 April 2022
                11 April 2022
                February 2023
                : 38
                : 2
                : 315-323
                Affiliations
                [1 ]GRID grid.10586.3a, ISNI 0000 0001 2287 8496, Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, , University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, ; Murcia, Spain
                [2 ]GRID grid.415992.2, ISNI 0000 0004 0398 7066, Liverpool Centre for Cardiovascular Science, , University of Liverpool and Liverpool Heart and Chest Hospital, ; Liverpool, UK
                [3 ]GRID grid.10586.3a, ISNI 0000 0001 2287 8496, Department of Hematology and Clinical Oncology, Hospital General Universitario Morales Meseguer, , University of Murcia, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), ; Murcia, Spain
                [4 ]GRID grid.5117.2, ISNI 0000 0001 0742 471X, Department of Clinical Medicine, Aalborg Thrombosis Research Unit, , Aalborg University, ; Aalborg, Denmark
                Article
                7567
                10.1007/s11606-022-07567-5
                9905403
                35411538
                997682da-9c37-4857-b636-9eea06f27ca2
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 17 January 2022
                : 31 March 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100004587, Instituto de Salud Carlos III;
                Award ID: PI17/01375
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100012513, Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares;
                Award ID: CB16/11/00385
                Award Recipient :
                Categories
                Original Research
                Custom metadata
                © The Author(s), under exclusive licence to Society of General Internal Medicine 2023

                Internal medicine
                atrial fibrillation,abc pathway,integrated care,mortality,mace
                Internal medicine
                atrial fibrillation, abc pathway, integrated care, mortality, mace

                Comments

                Comment on this article